If you have been reading about TH9507 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
== Manufacture == Commercially prepared instant soups are usually dried or dehydrated, canned, or treated by freezing. Some dry instant soups are prepared with thickening ingredients, such as pregelatinized starch, that function at a lower temperature compared to others. Additional ingredients used in commercial instant soups to contribute to their consistency include maltodextrins, emulsified fat powders, sugars, potato starch, xanthan gum, and guar gum.
South Africa gradually became locked in a conventional arms race with Angola; each side argued that it had to match the increased force available to the other. To counter the appearance of advanced MiG-23 and SU-22 fighters in Angola, for instance, South Africa began development on two sophisticated fighter aircraft of its own, the Atlas Cheetah and the Atlas Carver. Both programmes would consume billions of rand.
=== Limitations === Limitations to their effectiveness, nevertheless, exist. Sometimes, protection fails for vaccine-related reasons such as failures in vaccine attenuation, vaccination regimens or administration. Failure may also occur for host-related reasons if the host's immune system does not respond adequately or at all. Host-related lack of response occurs in an estimated 2–10% of individuals, due to factors including genetics, immune status, age, health and nutritional status. One type of primary immunodeficiency disorder resulting in genetic failure is X-linked agammaglobulinemia, in which the absence of an enzyme essential for B cell development prevents the host's immune system from generating antibodies to a pathogen. Host–pathogen interactions and responses to infection are dynamic processes involving multiple pathways in the immune system. A host does not develop antibodies instantaneously: while the body's innate immunity may be activated in as little as twelve hours, adaptive immunity can take 1–2 weeks to fully develop. During that time, the host can still become infected. Once antibodies are produced, they may promote immunity in any of several ways, depending on the class of antibodies involved. Their success in clearing or inactivating a pathogen will depend on the amount of antibodies produced and on the extent to which those antibodies are effective at countering the strain of the pathogen involved, since different strains may be differently susceptible to a given immune reaction.
Carminic acid is a polyketide secondary metabolite produced by the scale insect Dacylopius coccus. In terms of its biosynthetic origin, the structure of carminic acid was speculated to be either from type ll polyketide or shikimate pathways. This claim was not disputed until a key intermediate exclusive to the polyketide pathway was isolated. Until then, a detailed biosynthetic mechanism had not been formally proposed. The biosynthesis of carminic acid can be divided into three stages. The initiation stage involves transferases that load acetyl (AT) and malonyl-CoA (MCAT) to the acyl carrier protein (ACP) forming acetyl and malonyl-ACP, respectively. The acetyl-ACP acts as a priming unit for the decarboxylative condensation with malonyl-CoA catalyzed by a ketoacyl synthase (KS) protein. The resulting acetoacetyl ACP is the simplest polyketide produced by this pathway, and it is subsequently condensed with six more malonyl-ACP units before cyclizing. The elongation stage consists of the repeated decarboxylative condensation by a ketoacyl synthase/chain length factor heterodimer that monitors the length of the growing polyketide. The resulting octaketide is then aromatized by a cyclase domain which catalyzes an aldol-like cyclization reaction resulting in the formation of a flavokermesic acid anthrone (FKA). In any polyketide-based pathway, flavokermesic acid anthrone is the first cyclic intermediate. It was the successful isolation and characterization of FKA in wild type coccids that strengthened the evidence of a polyketide mediated biosynthetic pathway.
In 1924, Gilbert Walker (for whom the Walker circulation is named) coined the term "Southern Oscillation". He and others (including Norwegian-American meteorologist Jacob Bjerknes) are generally credited with identifying the El Niño effect. The major 1982–83 El Niño led to an upsurge of interest from the scientific community. The period from 1991–1994 was unusual in that El Niños have rarely occurred in such rapid succession. An especially intense El Niño event in 1998 caused an estimated 16% of the world's reef systems to die. The event temporarily warmed air temperature by 1.5 °C, compared to the usual increase of 0.25 °C associated with El Niño events. Since then, mass coral bleaching has become common worldwide, with all regions having suffered "severe bleaching". In June 2026, the NOAA's Climate Prediction Center officially confirmed the return of El Niño, forecasting a strengthening of the phenomenon through the winter of 2026–2027. The agency estimated a 69% likelihood that the event would reach a historically significant intensity, ranking among the strongest El Niño episodes recorded since 1950.
Sources: en.wikipedia.org
The origins of alemtuzumab date back to Campath-1 which was derived from the rat antibodies raised against human lymphocyte proteins by Herman Waldmann and colleagues in 1983. The name Campath derives from the pathology department of Cambridge University. Initially, Campath-1 was not ideal for therapy because patients could, in theory, react against the foreign rat protein determinants of the antibody. To circumvent this problem, Greg Winter and his colleagues humanised Campath-1, by extracting the hypervariable loops that had specificity for CD52 and grafting them onto a human antibody framework. This became known as Campath-1H and serves as the basis for alemtuzumab. While alemtuzumab started life as a laboratory tool for understanding the immune system, within a short time it was clinically investigated for use to improve the success of bone marrow transplants and as a treatment for leukaemia, lymphoma, vasculitis, organ transplants, rheumatoid arthritis and multiple sclerosis.
The fission of one atom of uranium-235 releases 202.5 MeV (3.24×10−11 J) inside the reactor. That corresponds to 19.54 TJ/mol, or 83.14 TJ/kg. Another 8.8 MeV escapes the reactor as anti-neutrinos. When 23592U nuclei are bombarded with neutrons, one of the many fission reactions that it can undergo is the following (shown in the adjacent image):
Insulin aspart, sold under the brand name Novolog, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. It is generally used by injection under the skin (into the abdomen, buttocks, thighs, or upper arms) but may also be used by injection into a vein. Common side effects include low blood sugar, allergic reactions, itchiness, and pain at the site of injection. Other common side effects may include injection site reactions, itching, rash, lipodystrophy (skin thickening or pitting at the injection site), weight gain and swelling of hands and feet. Other serious side effects may include low blood potassium (hypokalemia), low blood sugar (hypoglycemia), and severe allergic reactions. Use in pregnancy and breastfeeding is generally safe. It works the same as human insulin by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver. It is a manufactured form of human insulin; where a single amino acid has been changed, specifically a proline with an aspartic acid at the B28 position. Insulin aspart was approved for medical use in the United States in 2000. In 2023, it was the 102nd most commonly prescribed medication in the United States, with more than 6 million prescriptions. Manufacturing involves yeast, which have had the gene for insulin aspart put into their genome. This yeast then makes the insulin, which is harvested from the bioreactor. It is on the World Health Organization's List of Essential Medicines.
In the absence of other glucogenic sources, the 2-carbon acetyl-CoA derived from the oxidation of fatty acids cannot produce a net yield of glucose via the citric acid cycle, since an equivalent two carbon atoms are released as carbon dioxide during the cycle. During ketosis, however, acetyl-CoA from fatty acids yields ketone bodies, including acetone, and up to ~60% of acetone may be oxidized in the liver to the pyruvate precursors acetol and methylglyoxal. Thus ketone bodies derived from fatty acids could account for up to 11% of gluconeogenesis during starvation. Catabolism of fatty acids also produces energy in the form of ATP that is necessary for the gluconeogenesis pathway.
Sources: en.wikipedia.org
==== European Union ==== The European Food Safety Authority (EFSA) in 2016 reviewed the current evidence, finding the relationship between serum 25(OH)D concentration and musculoskeletal health outcomes is widely variable. They considered that average requirements and population reference intake values for vitamin D cannot be derived and that a serum 25(OH)D concentration of 50 nmol/L was a suitable target value. For all people over the age of 1, including women who are pregnant or lactating, they set an adequate intake of 15 μg/day (600 IU). On the other hand, the EU Commission defined nutrition labelling for foodstuffs as regards recommended daily allowances (RDA) for vitamin D to 5 μg/day (200 IU) as 100%. The EFSA reviewed safe levels of intake in 2012, setting the tolerable upper limit for adults at 100 μg/day (4000 IU), a similar conclusion as the IOM. The Swedish National Food Agency recommends a daily intake of 10 μg (400 IU) of vitamin D3 for children and adults up to 75 years, and 20 μg (800 IU) for adults 75 and older. Non-government organisations in Europe have made their own recommendations. The German Society for Nutrition recommends 20 μg. The European Menopause and Andropause Society recommends postmenopausal women consume 15 μg (600 IU) until age 70, and 20 μg (800 IU) from age 71. This dose should be increased to 100 μg (4,000 IU) in some patients with very low vitamin D status or in case of co-morbid conditions.
==== American involvement ==== In the mid-2010s, the US identified China as a primary source of illicit fentanyl and other synthetic opioids. American anti-drug intervention regarding China is influenced and constrained by the geopolitical sensitivities of US-China relations. The US employs several approaches: exerting diplomatic pressure on China to impose internal controls on illicit drugs; seeking cooperation in US and international law enforcement efforts; unilaterally imposing targeted sanctions; and bringing criminal indictments against Chinese companies and individuals. The effectiveness of these approaches depends significantly on China's level of implementation and enforcement, which is directly related to the fluctuating state of overall US-China relations. Following China's scheduling of fentanyl-class substances in 2019, the flow of synthetic opioids from China to the US appeared to subside; trafficking from China shifted to precursor chemicals and related equipment, and Mexico's drug cartels emerged as major clients. In November 2023, President Biden announced an agreement with General Secretary Xi Jinping for China to crack down on the export of precursor chemicals and pill presses to the Western Hemisphere. A US House committee report released in April 2024 found companies making fentanyl precursors in China can still apply for Chinese state tax rebates and other financial benefits after exporting the product.
==== Objective Colour Analysis ==== Objective colour analysis can be performed using digital images taken with a digital camera, either in the field or in a laboratory. This method was developed to replace subjective colour reporting, such as by-eye observations, with quantitative RGB and HSV values. The method has previously been demonstrated on the thermal treatment of uranyl peroxide powders, which yield distinctive yellow to brown hues. Hence, this method is noted as particularly useful in determining thermal processing history, especially where colour changes occur in uranium compounds of various oxidation states.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.